Novel orally administered dosage form for...

Details Novel orally administered dosage form for... Novel orally administered dosage form for...

A - Human Necessities

61

K

A61K 31/4184 (2006.01) A61K 9/107 (2006.01) A61K 9/66 (2006.01) A61K 47/14 (2006.01)

Patent

CA 2537480

The invention relates to a novel orally administered dosage form for the active substance 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]- methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-ethyl proprionate and pharmacologically compatible salts thereof.

L'invention concerne une nouvelle forme galénique orale pour le principe actif éthylester d'acide 3-[(2-{[4-(hexyloxycarbonylamino-imino-méthyle)-phénylamino]-méthyle}-1-méthyle-1<I>H</I>-benzimidazol-5-carbonyle)-pyridine-2-yle-amino] propionique et ses sels pharmaceutiquement tolérables.

Affiliated with

Also associated with

Rating

Novel orally administered dosage form for... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Novel orally administered dosage form for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Novel orally administered dosage form for... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1968463